Abstract
IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy- Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.
Keywords: IMiDs, thalidomide, CC-5013, lenalidomide, CC-4047, pomalidomide, safety, side effects, CIPN
Mini-Reviews in Medicinal Chemistry
Title: Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Volume: 9 Issue: 7
Author(s): Sante Cundari and Guido Cavaletti
Affiliation:
Keywords: IMiDs, thalidomide, CC-5013, lenalidomide, CC-4047, pomalidomide, safety, side effects, CIPN
Abstract: IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy- Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.
Export Options
About this article
Cite this article as:
Cundari Sante and Cavaletti Guido, Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives, Mini-Reviews in Medicinal Chemistry 2009; 9 (7) . https://dx.doi.org/10.2174/138955709788452595
DOI https://dx.doi.org/10.2174/138955709788452595 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Experimental Animal Models of Myocardial Damage in Regenerative Medicine Studies Involving Adult Bone Marrow Derived Stem Cells: Ethical and Methodological Implications
Cardiovascular & Hematological Disorders-Drug Targets miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Current Cancer Drug Targets Invasive Aspergillosis: Focus on New Approaches and New Therapeutic Agents
Current Medicinal Chemistry - Anti-Infective Agents The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets Editorial (Thematic Issue: Signal Transduction, Targeted Therapy and Cancer: From Bench to Clinics)
Current Pharmaceutical Design Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations
Current Topics in Medicinal Chemistry Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Inflammation & Allergy - Drug Targets (Discontinued) Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry Editorial [Hot Topic:Strategies for Molecular-Based Treatment of Hematological Malignancies (Guest Editor: Per Ole Iversen)]
Current Drug Targets Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Cardiotoxicity of 5-Fluorouracil
Cardiovascular & Hematological Agents in Medicinal Chemistry